The Middle EAST Chronic Lymphocytic Leukemia (CLL) Market was valued at USD 0.75 billion in 2024 and is projected to reach USD 1.50 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several factors, including the rising incidence of CLL, advancements in treatment options, and increasing awareness about the disease. The region is witnessing a growing demand...